Brexucabtagene autoleucel is a type of CAR T-cell therapy that is used to recognize blood cancer cells and eliminated them. The therapy is genetically modified T cells from the patient directed to CD19.
The drug is approved for adult patients with relapsed or refractory mantle cell lymphoma, under accelerated approval, and patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.